Mitiglinide is an anti-diabetic/anti-hyperglycemic compound that increases insulin secretion and decreases plasma glucose in pancreatic β cells. The short action of mitiglinide mimics the in vivo duration and timing of insulin release. Mitiglinide decreases levels of FGF-21, altering glucose metabolism. Mitiglinide directly inhibits ATP-sensitive K+ channels and may also activate ryanodine (RyR) receptors, altering intracellular Ca2+ release.

References


Caution: This product is intended for laboratory and research use only. It is not for human or drug use.